Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225387 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

A Phase 4 study of Lupus Nephritis, sponsored by NephroNet.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
7
Study locations

NCT07225387: Recruiting Phase 4 study of Lupus Nephritis, sponsored by NephroNet.

NCT07225387 is a Phase 4 study of Lupus Nephritis that is actively recruiting participants, run by NephroNet. The registered enrollment target is 30 participants, below the 309-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225387, a Phase 4 study of Lupus Nephritis, is actively recruiting participants, sponsored by NephroNet.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
7
Study locations

Study Summary

This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.

Primary Outcome

Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 12 months. CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not \>20% below baseline, no rescue meds, sustained on repeat assessment 30 days later.

Conditions Studied

Interventions

  • DRUG Voclosporin

Study Locations (7)

Georgia

  • Piedmont Physicians Rheumatology - Atlanta
  • Georgia Nephrology Research Institute - Lawrenceville
  • Parris & Associates - Lawrenceville

Arizona

  • AARA Clinical Research - Glendale

Ohio

  • Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center - Columbus

Oklahoma

  • Oklahoma Medical Research Foundation - Oklahoma City

Texas

  • AARA Clinical Research - Fort Worth

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-10-01
Est. Completion 2027-01
Phase Phase 4
NephroNet

2 total trials

What NCT07225387 shows while recruiting

NCT07225387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 309-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Voclosporin is the first listed.

NCT07225387 lists 7 locations in 5 states (Georgia, Arizona, Ohio).

Frequently Asked Questions

What is clinical trial NCT07225387 about?

NCT07225387 is a clinical study titled "Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial". This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) com...

What is the current status of trial NCT07225387?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-10-01. Estimated completion is 2027-01.

What conditions does trial NCT07225387 study?

This clinical trial studies the following conditions: Lupus Nephritis.

What interventions are being tested in trial NCT07225387?

The interventions under investigation include: Voclosporin (DRUG).

Who is sponsoring clinical trial NCT07225387?

This trial is sponsored by NephroNet, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225387 being conducted?

This trial has 7 study locations across Arizona, Georgia, Ohio, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lupus Nephritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07225387's enrollment target sits among peer trials

30 24th of 30 higher than 7 of 30 other Lupus Nephritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07225387, the US trial registry maintained by the National Library of Medicine. NCT07225387 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.